Notch1 expression, which is related to p65 status, is an independent predictor of prognosis in colorectal cancer

Clinical Cancer Research

Volumn 17, Issue 17, 2011, Pages 5686-5694

  Chu, Dake ^a   Zhou, Yi ^c   Zhang, Zixi ^a   Li, Yuming ^b   Li, Jipeng ^a   Zheng, Jianyong ^a   Zhang, Hongwei ^a   Zhao, Qingchuan ^a   Wang, Weizhong ^a   Wang, Rui'an ^a   Ji, Gang ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c Tianjin Union Medicine Centre   (China)

Author keywords

[No Author keywords available]

Indexed keywords

NOTCH1 RECEPTOR; SYNAPTOTAGMIN I;

ADULT; ARTICLE; CANCER SURVIVAL; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SURVIVAL TIME;

AGED; CARRIER PROTEINS; COHORT STUDIES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NF-KAPPA B; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECEPTOR, NOTCH1; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 80052446486     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-3196     Document Type: Article

References (43)

1. Greenwald I. LIN-12/Notch signaling: Lessons from worms and flies. Genes Dev 1998;12:1751-1762 (Pubitemid 28304327)
2. Artavanis-Tsakonas S., Rand M.D., Lake R.J. Notch signaling: Cell fate control and signal integration in development. Science 1999;284:770-776 (Pubitemid 29291335)
3. Blaumueller C.M., Qi H., Zagouras P., Artavanis-Tsakonas S. Intracellular cleavage of Notch leads to a heterodimeric receptor on the plasma membrane. Cell 1997;90:281-291 (Pubitemid 27329713)
4. Bigas A., Martin D.I., Milner L.A. Notch1 and Notch2 inhibit myeloid differentiation in response to different cytokines. Mol Cell Biol 1998;18:2324-2333 (Pubitemid 28152679)
5. Mumm J.S., Kopan R. Notch signaling: From the outside in. Dev Biol 2000;228:151-165 (Pubitemid 32011983)
6. Aster J.C., Xu L., Karnell F.G., Patriub V., Pui J.C., Pear W.S. Essential roles for ankyrin repeat and transactivation domains in induction of T-cell leukemia by notch1. Mol Cell Biol 2000;20:7505-7515
7. Bresnick E.H., Chu J., Christensen H.M., Lin B., Norton J. Linking Notch signaling, chromatin remodeling, and T-cell leukemogenesis. J Cell Biochem 2000;Suppl 35:46-53.
8. Struhl G., Adachi A. Nuclear access and action of notch in vivo. Cell 1998;93:649-660 (Pubitemid 28240725)
9. Schroeter E.H., Kisslinger J.A., Kopan R. Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. Nature 1998;393:382-386 (Pubitemid 28269713)
10. Weng A.P., Aster J.C. Multiple niches for Notch in cancer: Context is everything. Curr Opin Genet Dev 2004;14:48-54. (Pubitemid 38167477)
11. Weng A.P., Nam Y., Wolfe M.S., Pear W.S., Griffin J.D., Blacklow S.C., et al. Growth suppression of pre-T acute lymphoblastic leukemia cells by inhibition of notch signaling. Mol Cell Biol 2003;23:655-664 (Pubitemid 36050558)
12. Reedijk M., Odorcic S., Chang L., Zhang H., Miller N., McCready D.R., et al. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 2005;65:8530-8537 (Pubitemid 41330622)
13. Sriuranpong V., Borges M.W., Ravi R.K., Arnold D.R., Nelkin B.D., Baylin S.B., et al. Notch signaling induces cell cycle arrest in small cell lung cancer cells. Cancer Res 2001;61:3200-3205 (Pubitemid 32691976)
14. Leong K.G., Gao W.Q. The Notch pathway in prostate development and cancer. Differentiation 2008;76:699-716. (Pubitemid 352036647)
15. Benne C., Lelievre J.D., Balbo M., Henry A., Sakano S., Levy Y. Notch increases T/NK potential of human hematopoietic progenitors and inhibits B cell differentiation at a pro-B stage. Stem Cells 2009;27:1676-1685
16. Nicolas M., Wolfer A., Raj K., Kummer J.A., Mill P., Van Noort M., et al. Notch1 functions as a tumor suppressor in mouse skin. Nat Genet 2003;33:416-421 (Pubitemid 36278861)
17. Sriuranpong V., Borges M.W., Ravi R.K., Arnold D.R., Nelkin B.D., Baylin S.B., et al. Notch signaling induces cell cycle arrest in small cell lung cancer cells. Cancer Res 2001;61:3200-3205 (Pubitemid 32691976)
18. Chu D., Wang W., Xie H., Li Y., Dong G., Xu C., et al. Notch1 expression in colorectal carcinoma determines tumor differentiation status. J Gastrointest Surg 2009;13:253-260
19. Chu D., Zheng J., Wang W., Zhao Q., Li Y., Li J., et al. Notch2 expression is decreased in colorectal cancer and related to tumor differentiation status. Ann Surg Oncol 2009;16:3259-3266
20. Chu D., Li Y., Wang W., Zhao Q., Li J., Lu Y., et al. High level of Notch1 protein is associated with poor overall survival in colorectal cancer. Ann Surg Oncol 2010;17:1337-1342
21. Chu D., Zhang Z., Zhou Y., Wang W., Li Y., Zhang H., et al. Notch1 and Notch2 have opposite prognostic effects on patients with colorectal cancer. Ann Oncol 2011 Mar 4. [Epub ahead of print].
22. Bremnes R.M., Veve R., Gabrielson E., Hirsch F.R., Baron A., Bemis L., et al. High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small- cell lung cancer. J Clin Oncol 2002;20:2417-2428 (Pubitemid 34525727)
23. Xie W., Mertens J.C., Reiss D.J., Rimm D.L., Camp R.L., Haffty B.G., et al. Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: A tissue microarray study. Cancer Res 2002;62:497-505. (Pubitemid 34106424)
24. Chung G.G., Provost E., Kielhorn E.P., Charette L.A., Smith B.L., Rimm D.L. Tissue microarray analysis of beta-catenin in colorectal cancer shows nuclear phospho-beta-catenin is associated with a better prognosis. Clin Cancer Res 2001;7:4013-4020 (Pubitemid 34044621)
25. Lee H.S., Cho S.B., Lee H.E., Kim M.A., Kim JH, Park do J, et al. Protein expression profiling and molecular classification of gastric cancer by the tissue array method. Clin Cancer Res 2007;13:4154-4163 (Pubitemid 47105978)
26. Efstratiadis A., Szabolcs M., Klinakis A. Notch, Myc and breast cancer. Cell Cycle 2007;6:418-429 (Pubitemid 46393444)
27. Rhodes A., Jasani B., Barnes D.M., Bobrow L.G., Miller K.D. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: Interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol 2000;53:125-130 (Pubitemid 30075056)
28. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
29. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
30. Wolpin B.M., Meyerhardt J.A., Mamon H.J., Mayer R.J. Adjuvant treatment of colorectal cancer.CA Cancer J Clin 2007;57:168-185 (Pubitemid 46798625)
31. Center M.M., Jemal A., Smith R.A., Ward E. Worldwide variations in colorectal cancer. CA Cancer J Clin 2009;59:366-378
32. Ryan C.J., Smith M.R., Fong L., Rosenberg J.E., Kantoff P., Raynaud F., et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010;28:1481-1488
33. Davicioni E., Anderson J.R., Buckley J.D., Meyer W.H., Triche T.J. Gene expression profiling for survival prediction in pediatric rhabdomyosarcomas: A report from the children's oncology group. J Clin Oncol 2010;28:1240-1246
34. Ferrari A., Miceli R., Meazza C., Casanova M., Favini F., Morosi C., et al. Comparison of the prognostic value of assessing tumor diameter versus tumor volume at diagnosis or in response to initial chemotherapy in rhabdomyosarcoma. J Clin Oncol 2010;28:1322-1328
35. Ejlertsen B., Jensen M.B., Nielsen K.V., Balslev E., Rasmussen B.B., Willemoe G.L., et al. HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients. J Clin Oncol 2010;28:984-990
36. Byrski T., Gronwald J., Huzarski T., Grzybowska E., Budryk M., Stawicka M., et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2010;28:375-379
37. Bray S.J. Notch signalling: A simple pathway becomes complex. Nat Rev Mol Cell Biol 2006;7:678-689 (Pubitemid 44268213)
38. Vilimas T., Mascarenhas J., Palomero T., Mandal M., Buonamici S., Meng F., et al. Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia. Nat Med 2007;13:70-77 (Pubitemid 46067388)
39. Van Waes C. Nuclear factor-kappaB in development, prevention, and therapy of cancer. Clin Cancer Res 2007;13:1076-1082 (Pubitemid 46424045)
40. Perkins N.D. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 2007;8:49-62. (Pubitemid 46012014)
41. Frasor J., Weaver A., Pradhan M., Dai Y., Miller L.D., Lin C.Y., et al. Positive cross-talk between estrogen receptor and NF-kappaB in breast cancer. Cancer Res 2009;69:8918-8925
42. Scartozzi M., Bearzi I., Pierantoni C., Mandolesi A., Loupakis F., Zaniboni A., et al. Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy. J Clin Oncol 2007;25:3930-3935 (Pubitemid 47477270)
43. Barré B., Perkins N.D. A cell cycle regulatory network controlling NF-kappaB subunit activity and function. EMBO J 2007;26:4841-4855 (Pubitemid 350191299)